Phase 1 trial of AZD0466
Phase of Trial: Phase I
Latest Information Update: 26 Sep 2019
Price : $35 *
At a glance
- Drugs AZD-0466 (Primary)
- Indications Haematological malignancies; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors AstraZeneca
- 26 Sep 2019 According to a Starpharma media release, the company anticipates to commence trial later this year.
- 26 Sep 2019 According to a Starpharma media release, U.S. Food and Drug Administration (FDA) has authorised the use of AZD0466 in clinical trials under an investigational new drug (IND) application.
- 16 Jul 2019 According to a Starpharma media release, US Food and drug administration investigational new drug application (IND) for AZD0466 is planned in the near future with the product expected to enter the clinic later this year.